Question 1

What are the main differences between TX05 and Herceptin®?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my treatment plan change if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of TX05 compared to Herceptin®?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures involved in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer clinical trial (NCT03556358). Contact the study team or your healthcare provider for specific answers.

What this study is about